We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Consensus vs. actual, and revenue trend
Consensus PT $270.28 · 21 analysts
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Stored first · Google News · Yahoo Finance (English)
Axsome Therapeutics (AXSM) Valuation Check After Strong Recent Share Price Momentum - simplywall.st
Axsome Therapeutics (AXSM) Valuation Check After Strong Recent Share Price Momentum simplywall.st
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Given Average Rating of "Moderate Buy" by Brokerages MarketBeat
[144] Axsome Therapeutics, Inc. SEC Filing - Stock Titan
[144] Axsome Therapeutics, Inc. SEC Filing Stock Titan
9,605 Shares in Axsome Therapeutics, Inc. $AXSM Bought by Integrity Alliance LLC. - MarketBeat
9,605 Shares in Axsome Therapeutics, Inc. $AXSM Bought by Integrity Alliance LLC. MarketBeat
Axsome Therapeutics to Present Clinical Program Updates at Investor Conferences - geneonline.com
Axsome Therapeutics to Present Clinical Program Updates at Investor Conferences geneonline.com
| Quarter | Date | Time | EPS est. | EPS actual | Surprise | Rev. est. | Rev. actual | Status |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 08. 03. | After market close (AMC) | $-0.82 | — | — | $222.38M | — | Scheduled |
| FY2026 Q1 | 2025. 03. 31. | Time TBD | — | $-1.22 | — | — | $121.46M | Reported |
| FY2025 Q3 | 2024. 09. 30. | Time TBD | — | $-4.45 | — | — | $266.93M | Reported |
| FY2025 Q2 | 2024. 06. 30. | Time TBD | — | $-3.11 | — | — | $162.17M | Reported |
| Date | Firm | Analyst | Action | Rating change | Price target | Report |
|---|---|---|---|---|---|---|
| 2026. 05. 06. | Morgan Stanley | — | Maintain | Equal-Weight → Equal-Weight | — | Morgan Stanley: Equal-Weight |
| 2026. 05. 05. | RBC Capital | — | Maintain | Outperform → Outperform | — | RBC Capital: Outperform |
| 2026. 05. 05. | Wells Fargo | — | Maintain | Overweight → Overweight | — | Wells Fargo: Overweight |
| 2026. 05. 05. | Guggenheim | — | Maintain | Buy → Buy | — | Guggenheim: Buy |
| 2026. 05. 05. | Mizuho | — | Maintain | Outperform → Outperform | — | Mizuho: Outperform |
| 2026. 05. 05. | Baird | — | Maintain | Outperform → Outperform | — | Baird: Outperform |
As of FY2026Q1 · Source: SEC/DART + price data
| # | Institution | Mandate | Shares | Value | Weight | Change | Position |
|---|---|---|---|---|---|---|---|
| 1 | Point72 Asset Management, L.P. | Point72 Asset Management, L.P. | 424,750 | $71.79B | 0.13% | — | New position |
| 2 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 322,778 | $54.56B | 0.05% | — | New position |
| 3 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 145,597 | $26.59B | 0.04% | — | New position |
| 4 | Point72 Asset Management, L.P. | Point72 Asset Management, L.P. | 17,999 | $3.29B | 0.01% | — | New position |